Clinique St Luc, Namur, Belgium.
Eur J Cardiothorac Surg. 2013 Nov;44(5):884-90. doi: 10.1093/ejcts/ezt137. Epub 2013 Mar 14.
The spread of drug-eluting stents (DES) has reduced the incidence of early restenosis following percutaneous coronary interventions (PCI). Meanwhile, development of minimally invasive coronary artery bypass surgery (MIDCAB) has offered a valuable alternative to conventional sternotomy with preservation of the benefit of the internal mammary artery use. Therefore, the revascularization of the left anterior descending (LAD) artery is suitable for both techniques. However, few data with long-term comparison of these two techniques exist.
Prospective data were collected for 456 patients undergoing isolated LAD revascularization between 1997 and 2011. Two hundred and sixty patients were treated with MIDCAB and 196 with first-generation DES implantation. A propensity score model was created to adjust for 19 relevant confounding variables. Primary and secondary end-points were, respectively, 5-year survival and freedom from major adverse cerebro-cardiovascular events (MACCE).
Both groups were similar in age, EuroSCORE and mean duration of follow-up. Five-year survival was similar after MIDCAB or DES (hazard ratio (HR): 0.95; P = 0.89). Freedom from MACCE was significantly in favour of the MIDCAB group (HR: 0.32, P < 0.0001), mainly triggered by high subsequent need for revascularization of the targeted vessel in the DES group (HR: 0.17, P < 0.0001).
MIDCAB and DES implantation showed similar rates of survival but despite an expected lower rate of reintervention on the targeted vessel with DES use, a highly significant higher MACCE rate was observed in the PCI group at 5-year follow-up.
药物洗脱支架(DES)的应用降低了经皮冠状动脉介入治疗(PCI)后早期再狭窄的发生率。与此同时,微创冠状动脉旁路移植术(MIDCAB)的发展为传统的胸骨切开术提供了一种有价值的替代方法,同时保留了内乳动脉的使用优势。因此,左前降支(LAD)的血运重建适合这两种技术。然而,关于这两种技术的长期比较数据很少。
前瞻性收集了 1997 年至 2011 年期间 456 例接受孤立性 LAD 血运重建的患者数据。260 例患者接受 MIDCAB 治疗,196 例患者接受第一代 DES 植入治疗。创建倾向评分模型以调整 19 个相关混杂变量。主要和次要终点分别为 5 年生存率和免于主要不良心脑血管事件(MACCE)。
两组患者在年龄、EuroSCORE 和平均随访时间方面相似。MIDCAB 或 DES 后 5 年生存率相似(风险比(HR):0.95;P = 0.89)。MIDCAB 组免于 MACCE 的比例明显更高(HR:0.32,P < 0.0001),主要是由于 DES 组目标血管需要后续血运重建的比例较高(HR:0.17,P < 0.0001)。
MIDCAB 和 DES 植入的生存率相似,但尽管 DES 治疗的目标血管再介入率预期较低,但在 5 年随访时,PCI 组的 MACCE 发生率明显更高。